Determination of silybin content in food supplements containing silymarin

Martin Poruba, Zuzana Matušková

Klin Farmakol Farm. 2018;32(3):3-6 | DOI: 10.36290/far.2018.015  

The aim of this study was to determine the amount of silybin in selected nutraceuticals containing silymarin available in the CzechRepublic. The determination of silybin was performed using HPLC/UV. Results show that almost all of the tested nutraceuticalscontain the sufficient amount of silybin (range 20–40 %). NaturProdukt® Silymarin forte contained 40 % of silybin (80.00 ± 0.50 mg)and Nefdesanté® Silymarin ostropestřec contained 33 % of silybin (81.58 ± 0.14 mg). Both can be included among the products withhigh silybin content. On the other hand, the lowest amount of silybin was measured in WALMARK® Ostropestřec mariánský...

Pharmacotherapy of inflammatory boweldisease

Hana Dujsíková

Klin Farmakol Farm. 2018;32(3):7-10 | DOI: 10.36290/far.2018.016  

Inflammatory bowel disease means Crohn’s disease and ulcerative colitis. Mostly, it affects ileocecal area, resp. large intestine.Ethiology of the disease is unknown. The start of the disease is formed by a number of factors. This fact does not enable causaltreatment; treatment is possible only as symptomatic. Basic drug groups that are used for treatment of inflammatory boweldisease are aminosalicylates, corticoids, immunosuppressive therapy and biological therapy. As a supplementary treatment canbe considered antibiotics, probiotics; in specific cases parenteral or enteral nourishment is prescribed. Treatment is individuallychosen for each...

Vedolizumab, its pharmacological profile and therapeutic use

Tomáš Douda

Klin Farmakol Farm. 2018;32(3):11-14 | DOI: 10.36290/far.2018.017  

Vedolizumab (VDZ), a humanized monoclonal antibody, is approved for use in ulcerative colitis and Crohn’s disease (IBD).Vedolizumabinhibits leukocyte vascular adhesion and migration into the gastrointestinal tract through α4β7 integrin blockade. Clinicaleffectiveness of vedolizumab was evident in both the CD and mainly in UC populations. These findings are consistent withobservations from clinical trials, and from real word experience too. The improved safety profile, novel mechanism of action andclinical need for new therapies has led to the rapid adoption of vedolizumab use in clinical practice.

News in systemic treatment of advanced and metastatic carcinoma of the stomach

Dagmar Brančíková, Michal Eid

Klin Farmakol Farm. 2018;32(3):15-18 | DOI: 10.36290/far.2018.018  

Although the incidence of gastric cancer progressively decreases, high mortality still persists and stomach cancer is one of themost aggressive diseases. Based on the meta-analysis of the benefit of chemotherapy in palliative treatment, for good combinationregimens with fluorouracil were evaluated oxaliplatin, irinothecan and docetaxel in first-line treatment, and the benefit ofanthracyclines and capecitabine would be assessed as unconvincing. The standard for treatment of the first line in HER-positivecarcinoma has become a combination with trastuzumab; for the II line treatment, however, no further HER receptor blockershave been confirmed as effective....

Selected biological drugs in non-oncological indications

Petra Matalová

Klin Farmakol Farm. 2018;32(3):19-25 | DOI: 10.36290/far.2018.019  

Progress in developing new monoclonal antibodies allows us to affect pathological immune processes on many different levels.For treatment of different diseases, we now have available monoclonal antibodies. Also, the development of new humanized andhuman antibodies caused significant improvement of their safety profile. This article briefly summarizes the antibodies used innon-oncological indications.

Treating pain with the fixed combination of diclofenac and orphenadrine

Tomáš Vymazal, Karel Urbánek

Klin Farmakol Farm. 2018;32(3):26-33 | DOI: 10.36290/far.2018.020  

The fixed combination of orphenadrine and diclofenac for injection is characterized by the advantageous combination of analgesicand central myorelaxation effects. Its pharmacokinetics allows simple dosing once to twice a day and can significantly simplifyperioperative management of good analgesia by eliminating the risks associated with the repeated preparation and administrationof other analgesics. In common clinical practice, it is also used for the treatment of acute exacerbation of low back pain or inthe post-operative pain management. It also has an good safety profile.

Amiodarone induced acute hepatotoxicity during intravenous application

Jana Ďuricová, Marcela Káňová, Ivana Kacířová

Klin Farmakol Farm. 2018;32(3):34-37 | DOI: 10.36290/far.2018.031  

Amiodarone is considered a very effective agent in the treatment of supraventricular and ventricular arrhythmias. It has a goodhaemodynamic profile with a low arrhythmogenic risk. However, its use is associated with many cardiac and extracardiac adverseeffects. Hepatotoxicity during long-term amiodarone administration is relatively frequent. Asymptomatic elevation of transaminasesis reported with incidence about 25 %, with normalisation after dose reduction or amiodarone discontinuation. On the otherhand, acute hepatotoxicity during intravenous amiodarone application is rare. This article presents a case of a patient admittedto the intensive care unit...

The problems of alopecia in young women

Anna Hudáková, Ľudmila Majerníková, Gabriela Kuriplachová, Viera Sabolová

Klin Farmakol Farm. 2018;32(3):38-42 | DOI: 10.36290/far.2018.021  

The article is providing a complete owerview on the issues and treatment of alopecia in young women. On the basis of detailedanalysis of the case we have found that the disease affects on teraphy in women. Irreplaceable role in the successful treatment ofalopecia is not only a wide range of therapeutic procedures, as well as access to patient medical, psychological care and adequatesupport from relatives and close friends.

Vzpomínka na doc. MUDr. Otto Mayera, CSc.

Milan Grundmann

Klin Farmakol Farm. 2018;32(3):43-44